Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches

Cancer
Masato SakonMorito Monden

Abstract

The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor. Eleven consecutive patients with HCC and Vp3 were treated with 2-6 cycles of a "basic" combination therapy consisting of continuous arterial infusion of 5-fluorouracil (450-500 mg/day, for the initial 2 weeks) and subcutaneous injection of interferon-alpha (5 million international units, 3 times/week, 4 weeks). In the first 3 patients, methotrexate (90 mg/day 1 of every week), cisplatin (10 mg/day), and leucovorin (30 mg/days 2 and 3 of every week) also were administered for the initial 2 weeks ("full" regimen). In 8 (73%) of 11 patients, an objective response (complete response [CR] or partial response [PR]) was observed with marked regression of tumor and decrease in tumor markers. The use of the full regimen was associated with objective response in all patients; instead, they developed thrombocytopenia or leukopenia. In the subsequent 8 patients with basic regimen, 5 patients showed CR (2 cases) or PR (3 cases; objective response rate, 63%), and leukopenia was observed only in 1 patient. Simple combination therapy with subcutaneous interferon-alpha and intraarterial 5-fluorouracil therefore is a promi...Continue Reading

References

Feb 14, 1992·Biochemical and Biophysical Research Communications·E L SchwartzS Wadler
Sep 15, 1989·Biochemical and Biophysical Research Communications·L Elias, J M Sandoval
Mar 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·P LindahlI Gresser
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
May 1, 1995·Journal of Gastroenterology and Hepatology·F S YenS D Lee
Mar 1, 1993·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·C L LaiH J Lin
Jan 4, 1998·Journal of Gastroenterology and Hepatology·D Y LinY F Liaw
Sep 10, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases
May 29, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·H YanoM Kojiro
Dec 29, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J M LlovetJ Bruix

❮ Previous
Next ❯

Citations

Jul 5, 2005·Journal of Hepato-biliary-pancreatic Surgery·Takefumi NigumaNobumasa Tutui
Jun 19, 2007·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Sachiko OgasawaraMasamichi Kojiro
Sep 21, 2006·Journal of Gastroenterology and Hepatology·Hirohisa YanoMasamichi Kojiro
Mar 11, 2009·Journal of Biomedical Science·Pablo MatarGuillermo Mazzolini
Apr 6, 2006·Internal Medicine·Kiwamu Okita
Jan 28, 2010·Journal of Clinical Biochemistry and Nutrition·Naruaki KohgeYoshikazu Kinoshita
Apr 17, 2013·International Journal of Oncology·Hironori KusanoHirohisa Yano
Apr 18, 2013·Surgery Today·Satoshi Katagiri, Masakazu Yamamoto
Dec 9, 2014·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Bohuslav MelicharAntonin Krajina
Oct 31, 2006·Expert Review of Anticancer Therapy·Tsutomu MasakiShigeki Kuriyama
Jan 13, 2016·Cancer Chemotherapy and Pharmacology·Hiroaki NagamatsuTakuji Torimura
Nov 5, 2013·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·K TanakaI Endo
May 3, 2011·Journal of the American College of Surgeons·Hiroyuki YoshidomeMasaru Miyazaki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.